Main Products/ Pipelines & Platforms
IA-05 is a truncated QS-21 analogue with improved tolerability, stability, and long-term immune responses in combination of various antigens. IA-05 is expected to lead novel utilities in development of immunotherapies and therapeutic vaccines.
IA-05 is a truncated QS-21 analogue with improved tolerability, stability, and long-term immune responses in combination of various antigens. IA-05 is expected to lead novel utilities in development of immunotherapies and therapeutic vaccines.
Business Interests
In-Licensing, Out-Licensing, Collaborative R&D, Co-Development
Contact Info
Mu-Tzu Chu
Project Manager
+886-2-8797-5667
clairechu@immunadd.com